Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $25.10 USD
Change Today +2.18 / 9.51%
Volume 732.8K
WMGI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
NASDAQ GM
As of 10:45 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

wright medical group inc (WMGI) Snapshot

Open
$25.50
Previous Close
$22.92
Day High
$25.75
Day Low
$25.00
52 Week High
10/29/14 - $32.65
52 Week Low
08/21/15 - $22.17
Market Cap
1.3B
Average Volume 10 Days
495.9K
EPS TTM
$-4.21
Shares Outstanding
51.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WRIGHT MEDICAL GROUP INC (WMGI)

wright medical group inc (WMGI) Related Businessweek News

No Related Businessweek News Found

wright medical group inc (WMGI) Details

Wright Medical Group, Inc., a specialty orthopaedic company, provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients’ lifestyles worldwide. The company offers products that are used primarily in foot and ankle repair, upper extremity products, and biologics products. Its extremity hardware products include implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, fingers, toes, elbow, and shoulder. The company also provides biologic products, which are used to support treatment of damaged or diseased bone, and tendons and soft tissues; and other biological solutions for surgeons and their patients, as well as offers a bone graft product incorporating antibiotic delivery. Its biological products focus on supporting biological musculoskeletal repair by utilizing synthetic and human tissue-based materials. The company sells its products through a network of employee sales representatives, independent sales representatives, and stocking distributors. Wright Medical Group, Inc. was founded in 1950 and is headquartered in Memphis, Tennessee.

1,180 Employees
Last Reported Date: 02/26/15
Founded in 1950

wright medical group inc (WMGI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $750.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $354.6K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $500.0K
President of U.S. Extremities
Total Annual Compensation: $641.0K
President of International
Total Annual Compensation: $564.0K
Compensation as of Fiscal Year 2014.

wright medical group inc (WMGI) Key Developments

Wright Medical Group, Inc.'s BioMimetic Subsidiary Receives FDA Approval Order for AUGMENT(R) Bone Graft

Wright Medical Group Inc. announced that its BioMimetic subsidiary has received an approval order from the U.S. Food and Drug Administration (FDA) for its Premarket Approval Application (PMA) for AUGMENT® Bone Graft. The approval order indicates that FDA determined that AUGMENT® Bone Graft is safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications. Wright can now initiate commercial sale and distribution of AUGMENT® Bone Graft in the U.S. The company continues to anticipate AUGMENT® revenue in the U.S. to be in the range of $10 million to $12 million in the first seven to eight months post-approval. The revenue ramp is expected to build gradually during the first six months following the launch of the product as launch activities, such as review by hospital value analysis committees and physician education, are initiated. The company expects to begin selling product in the U.S. in the next several weeks once inventory is moved into its U.S. distribution network. AUGMENT® Bone Graft is the first clinically proven protein therapeutic to come to the U.S. orthopaedics market in over a decade, offering an alternative to autograft in ankle and/or hindfoot fusion procedures, which translates into an estimated market opportunity of approximately $300 million in the U.S. The combination of two components, recombinant human Platelet-Derived Growth Factor (rhPDGF) and Beta-tricalcium phosphate (Beta-TCP), is key to the product’s activities. rhPDGF provides a biological stimulus for the recruitment and proliferation of cells, including osteoblasts, which are responsible for the formation of bone, while Beta-TCP provides a framework or scaffold for new bone growth to occur. As an FDA-approved alternative to autograft in ankle and/or hindfoot fusion procedures, AUGMENT® offers a clear patient benefit by avoiding secondary surgical sites for the harvest of autograft tissue, which can result in prolonged harvest site pain in some patients.

Wright Medical Group, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015

Wright Medical Group Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of $80,420,000 against $72,364,000 a year ago. Operating loss was $34,342,000 against $29,171,000 a year ago. Loss from continuing operations before income taxes was $37,148,000 against $51,613,000 a year ago. Net loss from continuing operations was $37,306,000 or $0.73 basic and diluted per share against $53,583,000 or $1.08 basic and diluted per share a year ago. Net loss was $44,315,000 or $0.87 basic and diluted per share against $56,226,000 or $1.13 basic and diluted per share a year ago. International net sales were $22,150,000. Operating loss, as adjusted was $22,167,000 against $21,990,000 a year ago. EBITDA was $18,206,000 against $40,167,000 a year ago. Adjusted EBITDA was $10,865,000 against $11,565,000 a year ago. Loss before taxes, as adjusted was $27,085,000 against $23,638,000 a year ago. Net loss from continuing operations, as adjusted was $27,270,000 or $0.53 diluted per share against $23,962,000 or $0.48 diluted per share a year ago. Net cash used in operating activities was $25,754,000 against $24,350,000 a year ago. Capital expenditures were $13,900,000 against $16,448,000 a year ago. Net sales representing an 11% increase as reported and 15% increase on a constant currency basis compared to the second quarter of 2014. For the six months, the company reported net sales of $158,354,000 against $143,426,000 a year ago. Operating loss was $67,463,000 against $52,217,000 a year ago. Loss from continuing operations before income taxes was $83,230,000 against $94,081,000 a year ago. Net loss from continuing operations was $83,554,000 or $1.64 basic and diluted per share against $83,881,000 or $1.71 basic and diluted per share a year ago. Net loss was $94,063,000 or $1.85 basic and diluted per share against $86,646,000 or $1.76 basic and diluted per share a year ago. International net sales were $42,598,000. Operating loss, as adjusted was $44,212,000 against $36,488,000 a year ago. EBITDA was $48,745,000 against $72,071,000 a year ago. Adjusted EBITDA was $22,703,000 against $17,752,000 a year ago. Loss before taxes, as adjusted was $52,821,000 against $40,004,000 a year ago. Net loss from continuing operations, as adjusted was $53,172,000 or $1.04 diluted per share against $40,520,000 or $0.82 diluted per share a year ago. Net cash used in operating activities was $51,000,000 against $51,590,000 a year ago. Capital expenditures were $25,754,000 against $24,284,000 a year ago. The company provided earnings guidance for the full year of 2015. For the year, the company continues to anticipate net sales of approximately $325 million to $335 million, representing constant currency growth of 13% to 16% from 2014. The company continues to anticipate 2015 adjusted negative EBITDA from continuing operations, as described in the GAAP to non-GAAP reconciliation provided later in this release, of $22.0 million to $27.0 million. The company continues to anticipate adjusted loss per share from continuing operations, including stock-based compensation, for full-year 2015 of $1.67 diluted per share to $1.77 diluted per share, based on approximately 51.1 million shares outstanding. While the amount of the non-cash stock-based compensation charges will vary depending upon a number of factors, the company currently estimates that the after-tax impact of those expenses will be approximately $0.24 per diluted share for the full-year 2015. The company's anticipated ranges for net sales, earnings and adjusted EBITDA from continuing operations are forward-looking statements, as are any other statements that anticipate or aspire to future events or performance. They are subject to various risks and uncertainties that could cause the company's actual results to differ materially from the anticipated targets. The anticipated targets are not predictions of the company's actual performance.

Tornier N.V., Wright Medical Group Inc., Special/Extraordinary Shareholders Meeting, Jun 18, 2015

Tornier N.V., Wright Medical Group Inc., Special/Extraordinary Shareholders Meeting, Jun 18, 2015., at 09:30 Central European Standard Time. Location: Prins Bernhardplein 200. Agenda: To consider shareholder approval of the proposed merger and the issuance of Tornier ordinary shares in connection with the merger in accordance with Dutch law; to consider change in the corporate name to Wright Medical Group N.V.; and to consider the election of new directors effective upon completion of the merger.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WMGI:US $25.10 USD +2.18

WMGI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $64.13 USD +0.60
ICU Medical Inc $110.51 USD +0.51
Orthofix International NV $37.12 USD +0.18
RTI Surgical Inc $6.16 USD +0.015
Tornier NV $24.18 USD +2.20
View Industry Companies
 

Industry Analysis

WMGI

Industry Average

Valuation WMGI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WRIGHT MEDICAL GROUP INC, please visit www.wmt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.